Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EPIXNASDAQ:GRTXNASDAQ:KZRNASDAQ:RTTRNASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPIXESSA Pharma$6.12-2.1%$8.32$2.56▼$11.67$270.75M1.62135,637 shs64,765 shsGRTXGalera Therapeutics$0.21+10.7%$0.20$0.09▼$3.59$11.29M2.172.35 million shs662,154 shsKZRKezar Life Sciences$0.79-1.3%$0.89$0.67▼$3.13$57.51M0.47693,085 shs577,467 shsRTTRRitter Pharmaceuticals$0.30-3.3%$2.99$0.15▼$1.27$13.71M-0.4314.23 million shs17,610 shsXOMAXOMA$25.36-1.1%$24.80$13.48▼$27.00$295.19M0.5820,852 shs6,778 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPIXESSA Pharma-2.34%-11.60%-30.86%-8.09%+133.21%GRTXGalera Therapeutics-5.82%-7.91%-18.44%+5.00%-93.36%KZRKezar Life Sciences-2.98%-1.86%-12.42%-2.38%-67.29%RTTRRitter Pharmaceuticals-1.94%+3.87%-20.59%-37.02%-65.29%XOMAXOMA-1.72%+5.73%+6.83%+24.41%+41.03%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPIXESSA Pharma1.6855 of 5 stars3.53.00.00.00.03.30.0GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences3.6295 of 5 stars3.21.00.04.61.11.71.3RTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA3.4897 of 5 stars3.51.00.03.02.31.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPIXESSA Pharma3.00Buy$16.50169.61% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/AKZRKezar Life Sciences2.33Hold$11.001,292.41% UpsideRTTRRitter PharmaceuticalsN/AN/AN/AN/AXOMAXOMA3.00Buy$74.00191.80% UpsideCurrent Analyst RatingsLatest XOMA, GRTX, KZR, RTTR, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AKZRKezar Life Sciences$7M8.22N/AN/A$2.58 per share0.31RTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/AXOMAXOMA$4.76M62.01N/AN/A$7.72 per share3.28Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/AXOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)Latest XOMA, GRTX, KZR, RTTR, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 million2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPIXESSA PharmaN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPIXESSA PharmaN/A40.7440.74GRTXGalera TherapeuticsN/A4.364.36KZRKezar Life Sciences0.0511.6611.66RTTRRitter PharmaceuticalsN/A3.673.67XOMAXOMA1.348.688.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPIXESSA Pharma75.12%GRTXGalera Therapeutics50.77%KZRKezar Life Sciences67.90%RTTRRitter Pharmaceuticals0.84%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipEPIXESSA Pharma14.70%GRTXGalera Therapeutics6.90%KZRKezar Life Sciences7.90%RTTRRitter Pharmaceuticals15.40%XOMAXOMA7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableGRTXGalera Therapeutics754.39 million50.64 millionOptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableXOMAXOMA1311.64 million10.80 millionOptionableXOMA, GRTX, KZR, RTTR, and EPIX HeadlinesSourceHeadlineXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)finance.yahoo.com - April 25 at 8:40 AMXOMA's (XOMA) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 25 at 8:09 AMXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)globenewswire.com - April 25 at 7:30 AMXOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30americanbankingnews.com - April 25 at 3:14 AMActym Therapeutics Appoints Thomas Smart as CEOprnewswire.com - April 24 at 9:00 AMXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsfinance.yahoo.com - April 20 at 9:43 AMXOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93americanbankingnews.com - April 17 at 2:58 AMXOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLCmarketbeat.com - April 9 at 9:43 PMXOMA Corporation Announces Closing of Tender Offerglobenewswire.com - April 3 at 9:00 AMXOMA Declares Quarterly Preferred Stock Dividendsglobenewswire.com - March 21 at 7:30 AMXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.globenewswire.com - March 19 at 4:05 PMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 8 at 1:03 PMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valuefinance.yahoo.com - March 8 at 7:51 AMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valueglobenewswire.com - March 8 at 7:30 AMXOMA to Present at Upcoming Investor Conferences in Marchglobenewswire.com - February 28 at 7:30 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMCompare with Maple Leaf Green World Inc (4HV0)msn.com - February 18 at 12:30 PMXOMA to acquire Kinnate Biopharmathepharmaletter.com - February 17 at 10:21 AMXOMA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 10:21 AMXOMA Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:21 AMBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharmabenzinga.com - February 16 at 1:37 PMXOMA Agrees to Acquire Kinnate Biopharmamarketwatch.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Ritter PharmaceuticalsNASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.